Table 2.
The association between BRD7, YB1 expression and clinicopathologic features of breast cancer
| Variables | YB1 expression | BRD7/YB1 expression | ||||
|---|---|---|---|---|---|---|
| Features | YB1H | YB1L | P | BRD7LYB1H | BRD7HYB1L | P |
| Age (Y) | ||||||
| <46 | 50 (45.5) | 56 (50.9) | 0.418 | 35 (49.3) | 32(45.1) | 0.737 |
| ≥46 | 60 (54.5) | 54 (49.1) | 36 (50.7) | 39(54.9) | ||
| Tumor size (%) | ||||||
| T1~2 | 50 (45.5) | 71 (64.5) | 0.008** | 31 (43.7) | 46 (64.8) | 0.020* |
| T3~4 | 60 (54.5) | 39 (35.5) | 40 (56.3) | 25 (35.2) | ||
| Nodal metastasis (%) | ||||||
| Absent | 23 (20.9) | 25 (22.7) | 0.567 | 15 (21.1) | 19 (26.8) | 0.432 |
| Present | 87 (79.1) | 85 (77.3) | 56 (78.9) | 52 (73.2) | ||
| Distant metastasis (%) | ||||||
| Absent | 94 (85.5) | 106 (96.4) | 0.005** | 60 (84.5) | 69 (97.2) | 0.009** |
| Present | 16 (14.5) | 4 (3.6) | 11 (15.5) | 2 (2.8) | ||
| TNM stage (%) | ||||||
| I~II | 65 (59.1) | 84 (76.4) | 0.018* | 41 (57.7) | 55 (77.5) | 0.038* |
| III~ IV | 45 (40.9) | 26 (23.6) | 30 (42.3) | 16 (22.5) | ||
| ER expression (%) | ||||||
| Negative | 57 (51.8) | 35 (32.4) | 0.004** | 46 (64.8) | 21 (30.4) | 0.000*** |
| Positive | 53 (48.2) | 73 (67.6) | 25 (35.2) | 48 (69.6) | ||
| PR expression (%) | ||||||
| Negative | 58 (52.7) | 37 (34.3) | 0.006** | 45 (63.4) | 23 (33.3) | 0.000*** |
| Positive | 52 (47.3) | 71 (65.7) | 26 (36.6) | 46 (66.7) | ||
| HER2 expression (%) | ||||||
| Negative | 39 (35.5) | 40 (37.0) | 0.808 | 25 (35.2) | 29 (42.0) | 0.407 |
| Positive | 71 (64.5) | 68 (63.0) | 46 (64.8) | 40 (58.0) | ||
In 220 patients, ER, PR and HER2 expression was not detected in two of the patients with low YB1 expression, and the median of YB1 or BRD7 expression was used as the cutoff value
Y Year, TNM Tumor-node-metastases, H High expression, L Low expression, P P values of two-sided χ2 test, % The ratio of the number of samples to the total number of samples per column, * p < 0.05, ** p < 0.01, *** p < 0.001